Clinical trial
A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
NCT02841995 is registered in ClinicalTrials.gov with Kadmon, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
- Lead sponsor
- Kadmon, a Sanofi Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 15, 2016
- Completion date
- May 12, 2022
- Enrollment
- 54 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.